Close Menu

More articles about Infectious Disease

French startup SeqOne has adapted its sequencing data-analysis platform to support a new method for high-throughput processing of coronavirus tests in its home country.

A handful of recently published trials suggest that use of the pneumonia panel could lead to more targeted therapy delivered more quickly than standard methods.

The two organizations announced a partnership earlier this year to manufacture and process Curative's oral fluid-based SARS-CoV-2 test.

The DeepChek-HIV assays are designed for settings running either Sanger sequencing or next-generation sequencing workflows, according to the company.

The listing enables assay developers and testing labs in the US to access the instrument for COVID-19 testing, the firm said.

The firm also received the CE mark for the test, which uses a reformulated buffer and takes less time to process than a test requiring an RNA extraction step.

The new funds will be used, in part, to support ChromaCode's expansion into resource-limited communities in low- to middle-income nations.

Swiss firm DKSH will market and sell Ubiquitome's Liberty16 PCR-based platform in Australia, New Zealand, and other countries in the region.

The study aims to enroll 20,000 existing Biobank participants, as well as their adult children and grandchildren, from England, Scotland, and Wales.

The FDA granted Emergency Use Authorization for Everlywell's at-home nasal swab collection kit, which can be used with Fulgent and Assurance's tests.

The acquisition will round out BD's molecular portfolio and be complementary to the firm's Veritor immunoassay system, according to executives. 

The PCR-based test works with upper and lower respiratory specimens, including nasal swabs and sputum, and can be performed by high complexity labs.

The group has completed a pilot study to understand the molecular epidemiology of the country's COVD-19 outbreak and to compare it to the global pandemic. 

Children's Hospital Los Angeles used a SARS-CoV-2 sequencing panel to determine if patients had become infected from the same source as healthcare workers.

The Cedars-Sinai Medical Center SARS-CoV-2 RT-PCR assay uses the A*Star Fortitude Kit 2.0 for the detection of SAR-CoV-2 specific RNA in nasopharyngeal swab samples.

Several groups are developing diagnostic viral genome sequencing assays and panels, which promise high sensitivity and additional information on viral origin and spread.

A recent study from New York University found Abbott's ID Now rapid point-of-care test could return false negative results.

The firm said it has begun distributing the Aptima SARS-CoV-2 test and expects to produce an average of 1 million per week.

Since the Salt Lake City-based company launched its SARS-CoV-2 test in March, it has recorded COVID-19-related test and equipment sales of over $18 million.

The research suggests that pangolins are natural hosts of Betacoronaviruses but does not support the idea that SARS-CoV-2 emerged directly from pangolins.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.